×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NTLA – intellia therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NTLA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
01:58 pm
ntla
Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory [Yahoo! Finance]
Low
Report
Intellia Therapeutics, Inc. (NTLA): A Bear Case Theory [Yahoo! Finance]
12/2
01:30 pm
ntla
Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility [Seeking Alpha]
Low
Report
Intellia Therapeutics: Critical Safety Updates Are Imminent - Expect Volatility [Seeking Alpha]
11/29
09:28 am
ntla
Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade [Yahoo! Finance]
Medium
Report
Intellia Therapeutics (NTLA): Valuation Insights After NTLA-2001 Safety Setback and Analyst Downgrade [Yahoo! Finance]
11/25
08:55 am
ntla
Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress [Yahoo! Finance]
Low
Report
Intellia Therapeutics (NTLA) Downgraded After Safety Concerns and Regulatory Delays Slow Gene-Editing Progress [Yahoo! Finance]
11/19
06:10 pm
ntla
KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight [Yahoo! Finance]
Medium
Report
KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight [Yahoo! Finance]
11/15
10:04 am
ntla
2 Beaten-Down Stocks to Avoid Right Now [Yahoo! Finance]
Low
Report
2 Beaten-Down Stocks to Avoid Right Now [Yahoo! Finance]
11/13
12:11 pm
ntla
Should You Buy the Dip in Intellia Therapeutics Stock? [Yahoo! Finance]
Medium
Report
Should You Buy the Dip in Intellia Therapeutics Stock? [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:00 pm
ntla
intellia therapeutics, inc.
BEAT
Report
-22.7%
intellia therapeutics, inc.
8/7/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
-1.7%
intellia therapeutics, inc.
5/8/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
9.5%
intellia therapeutics, inc.
2/27/2025
07:30 am
ntla
intellia therapeutics, inc.
BEAT
Report
-4.7%
intellia therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/12
03:55 pm
ntla
Form SCHEDULE 13G Intellia Therapeutics, Filed by: GOLDMAN SACHS GROUP INC
Low
Report
Form SCHEDULE 13G Intellia Therapeutics, Filed by: GOLDMAN SACHS GROUP INC
11/12
01:48 pm
ntla
Form SCHEDULE 13G Intellia Therapeutics, Filed by: Contrarius Investment Management Ltd
Low
Report
Form SCHEDULE 13G Intellia Therapeutics, Filed by: Contrarius Investment Management Ltd
11/10
05:25 pm
ntla
Form 8-K Intellia Therapeutics, For: Nov 08
Low
Report
Form 8-K Intellia Therapeutics, For: Nov 08
11/6
04:28 pm
ntla
Form 10-Q Intellia Therapeutics, For: Sep 30
High
Report
Form 10-Q Intellia Therapeutics, For: Sep 30
11/6
04:09 pm
ntla
Form 8-K Intellia Therapeutics, For: Nov 06
High
Report
Form 8-K Intellia Therapeutics, For: Nov 06
11/4
04:50 pm
ntla
Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: ARK Investment Management LLC
High
Report
Form SCHEDULE 13G/A Intellia Therapeutics, Filed by: ARK Investment Management LLC
10/29
04:23 pm
ntla
Form 8-K Intellia Therapeutics, For: Oct 29
Medium
Report
Form 8-K Intellia Therapeutics, For: Oct 29
10/3
05:14 pm
ntla
Form 4 Intellia Therapeutics, For: Oct 01 Filed by: Schultes Birgit C
Low
Report
Form 4 Intellia Therapeutics, For: Oct 01 Filed by: Schultes Birgit C
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/27
Intellia Therapeutics, Inc. (NTLA) Q4 2019 Earnings Call Transcript [The Motley Fool]
17.1%
10/31 Intellia Therapeutics, Inc. (NTLA) Q3 2019 Earnings Call Transcript [The Motley Fool] 9.0%
2/10 Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference 7.6%
11/23 More CRISPR Stock Catalysts Ahead [The Motley Fool] 6.3%
4/22 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.3%
6/7 Form EFFECT Intellia Therapeutics, 5.6%
2/5 Here's Why CRISPR Stocks Fell in January [The Motley Fool] 5.0%
10/31 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus -0.610 ActVsEst 0.120 - Beat 5.0%
3/26 Form 8-K Intellia Therapeutics, For: Mar 26 4.2%
7/8 Intellia +1% after Baird start at Outperform [Seeking Alpha] 4.2%
10/31 Intellia Therapeutics, Inc. (NTLA) Q3 2019 Earnings Call Transcript [The Motley Fool] 9.0%
2/10 Intellia Therapeutics Presents New Data From Its Engineered Cell Therapy and In Vivo Programs at Keystone Symposia’s Engineering the Genome Conference 7.6%
11/23 More CRISPR Stock Catalysts Ahead [The Motley Fool] 6.3%
4/22 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 6.3%
6/7 Form EFFECT Intellia Therapeutics, 5.6%
2/5 Here's Why CRISPR Stocks Fell in January [The Motley Fool] 5.0%
10/31 Q3/2019 9/30/2019 EPS -0.490 ZacksConsensus -0.610 ActVsEst 0.120 - Beat 5.0%
3/26 Form 8-K Intellia Therapeutics, For: Mar 26 4.2%
7/8 Intellia +1% after Baird start at Outperform [Seeking Alpha] 4.2%
TOP News Decliners
3/13
Form 8-K Intellia Therapeutics, For: Mar 12
-17.6%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
6/10 Intellia Therapeutics Inc (NASDAQ: NTLA) is now covered by analysts at Roth Capital. They set a "neutral" rating and a $16.00 price target on the stock. -10.3%
4/1 Intellia Therapeutics Inc (NASDAQ: NTLA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $57.50 price target on the stock. -8.8%
8/26 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.2%
4/28 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. -7.8%
9/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was given a new $57.50 price target on by analysts at Chardan Capital. They now have a "buy" rating on the stock. -7.7%
5/7 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -7.7%
4/30 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.6%
4/21 Intellia Therapeutics Inc (NASDAQ: NTLA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock. -7.5%
2/14 Intellia Therapeutics Inc (NASDAQ: NTLA) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. -7.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: